ZVSA

ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ZVSA

1 2 3 4 5 6 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/17	06:30	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/17	06:29	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	20:25	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	20:22	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	05:35	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	05:32	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	05:30	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/04	06:29	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/04	06:28	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/08/31	06:10	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/08/10	05:40	GlobeNewswire Inc.	ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/08/10	05:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/08/07	20:50	GlobeNewswire Inc.	ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/08/01	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/07/29	20:45	GlobeNewswire Inc.	ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/07/25	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/07/19	10:35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/07/19	10:35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/07/19	10:35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/07/19	00:18	GlobeNewswire Inc.	ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/07/17	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/07/09	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/05/15	21:35	GlobeNewswire Inc.	ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/05/15	21:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/05/15	21:25	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/05/14	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/04/29	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/04/04	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes	NASDAQ:ZVSA	ZyVersa Therapeutics Inc